news
New partnership established to develop an innovation lab
Google and Sanofi have partnered to develop an innovation lab for the advancement of health services.
List view / Grid view
Sanofi
news
Job cuts limit cardiovascular and diabetes research and development
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
news
Haseeb Ahmad has been named as the new president of ABPI
Haseeb Ahmad from Novartis Pharmaceuticals has been confirmed as the new president of the The Association of the British Pharmaceutical Industry (ABPI).
article
It’s not just about the science: microbiological analysis
Modernisation of microbiological test methods involves far more than just the science. As new systems and technologies become available it becomes increasingly important that potential users can identify not only the technical requirements, but also the business case. Here, Paul Newby, Alice Laures and Lisa Wysocki from GlaxoSmithKline discuss criteria…
news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
news
Committee demands answers on rising cost of insulin in the US
Letters have been sent to Eli Lilly, Novo Nordisk and Sanofi asking them to explain the rapidly increasing cost of insulin...
news
NIH partnership to improve clinical trials for Parkinson’s disease
The NIH is teaming with the government, biopharmaceutical, life science and non-profit organisations to overcome obstacles and increase success for advancing promising treatments for PD...
news
Sanofi to acquire haemophilia specialists Bioverativ for $11.6bn
Sanofi and Bioverativ Inc., have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ...
article
Sanofi: Unravelling the complex, together
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements...
article
21st Anniversary Supplement
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
article
Using quality as a lever for transformation
As part of EPR’s Women in Pharma series, Céline Schillinger, Head, Quality Innovation & Engagement at Sanofi Pasteur, talks to Science Editor Dr Zara Kassam about growing modern leadership skills, taking advantage of digital and social technologies and leveraging diversity in decision-making...
news
EC grants marketing authorisation of Dupixent for atopic dermatitis
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
news
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis...
news
Sanofi and Boehringer Ingelheim confirm closing of business swap date
6 June 2017 | By Niamh Marriott, Junior Editor
The strategic transaction, which consists of an exchange of Sanofi's animal health business & Boehringer Ingelheim's CHC business, has been closed in market
news
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
